HC Wainwright Reaffirms Buy Rating for Liquidia (NASDAQ:LQDA)

HC Wainwright reiterated their buy rating on shares of Liquidia (NASDAQ:LQDA) in a report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $32.00 target price on the stock. HC Wainwright also issued estimates for Liquidia’s Q4 2024 earnings at ($0.20) EPS, FY2024 earnings at ($1.18) EPS, FY2025 earnings at ($1.07) EPS, FY2026 earnings at ($1.07) EPS, FY2027 earnings at ($0.15) EPS and FY2028 earnings at $0.19 EPS.

Separately, Needham & Company LLC reaffirmed a buy rating and issued a $28.00 price objective on shares of Liquidia in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat, Liquidia currently has a consensus rating of Moderate Buy and an average price target of $21.00.

Liquidia Stock Performance

LQDA opened at $12.71 on Wednesday. Liquidia has a 1-year low of $5.71 and a 1-year high of $16.99. The stock’s 50 day simple moving average is $14.03 and its 200 day simple moving average is $11.90.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Wednesday, March 13th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.19). The business had revenue of $4.53 million during the quarter, compared to analysts’ expectations of $5.29 million. Liquidia had a negative return on equity of 177.83% and a negative net margin of 674.42%. On average, equities analysts expect that Liquidia will post -1.26 EPS for the current year.

Insider Buying and Selling at Liquidia

In other Liquidia news, General Counsel Russell Schundler sold 2,060 shares of the firm’s stock in a transaction on Friday, April 12th. The stock was sold at an average price of $14.58, for a total value of $30,034.80. Following the sale, the general counsel now directly owns 486,027 shares in the company, valued at $7,086,273.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, General Counsel Russell Schundler sold 2,060 shares of the stock in a transaction dated Friday, April 12th. The shares were sold at an average price of $14.58, for a total value of $30,034.80. Following the completion of the transaction, the general counsel now owns 486,027 shares in the company, valued at approximately $7,086,273.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Michael Kaseta sold 12,166 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $15.82, for a total value of $192,466.12. Following the sale, the chief financial officer now directly owns 318,181 shares in the company, valued at approximately $5,033,623.42. The disclosure for this sale can be found here. Insiders sold a total of 70,999 shares of company stock worth $1,100,444 over the last ninety days. Company insiders own 31.60% of the company’s stock.

Hedge Funds Weigh In On Liquidia

A number of institutional investors have recently bought and sold shares of LQDA. SG Americas Securities LLC purchased a new stake in shares of Liquidia in the third quarter worth approximately $84,000. Strs Ohio purchased a new stake in Liquidia in the 3rd quarter worth approximately $507,000. McAdam LLC acquired a new stake in shares of Liquidia during the 3rd quarter valued at $325,000. Sigma Planning Corp grew its holdings in shares of Liquidia by 5.4% during the 3rd quarter. Sigma Planning Corp now owns 95,640 shares of the company’s stock valued at $606,000 after acquiring an additional 4,885 shares in the last quarter. Finally, Aigen Investment Management LP acquired a new position in shares of Liquidia in the third quarter worth $80,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).